Physician profile
James O Patterson
NPI 1457352106
$8,202.38
in general payments reported to CMS, 2019-2025
30 companies · $1,671 in 2025
The $1,671 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,050 · 2020: $10.97 · 2021: $80.58 · 2022: $1,671 · 2023: $1,567 · 2024: $2,152 · 2025: $1,671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,389.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,660.68 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Gilead Sciences, INC. | $879.29 | 2022-2025 | Biktarvy |
| Novo Nordisk INC | $861.91 | 2022-2025 | Rybelsus, Wegovy, Ozempic |
| Theratechnologies INC. | $774.94 | 2022-2025 | Egrifta, Trogarzo |
| Merck Sharp & Dohme LLC | $750.46 | 2021-2025 | Pifeltro, Delstrigo, Dificid |
| Astrazeneca Pharmaceuticals LP | $669.23 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $411.00 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Viiv Healthcare Company | $365.39 | 2022-2025 | Cabenuva, Apretude, Rukobia |
| Bayer Healthcare Pharmaceuticals INC. | $304.26 | 2022-2025 | |
| Abbvie INC. | $266.07 | 2021-2025 | |
| Abbott Laboratories | $202.81 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $150.74 | 2024-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $119.65 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $97.60 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.57 | 2023-2025 | Jardiance, Synjardy |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $73.68 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $68.43 | 2021-2022 | |
| Janssen Biotech, INC. | $65.86 | 2022-2023 | Symtuza |
| Exact Sciences Corporation | $62.78 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $59.09 | 2022-2025 | Zoryve |
| Hikma Pharmaceuticals USA | $52.09 | 2023-2024 | Ryaltris, Mitigare |
| Amarin Pharma, INC. | $47.93 | 2022 | |
| Edwards Lifesciences Corporation | $31.47 | 2022 | |
| Myriad Genetic Laboratories, INC. | $25.43 | 2024 | Genesight |
| Amgen INC. | $19.89 | 2024 | Repatha, Otezla |
| Esperion Therapeutics, INC. | $19.75 | 2025 | Nexletol |
| Phathom Pharmaceuticals, INC. | $19.37 | 2025 | Voquezna |
| Xeris Pharmaceuticals, INC. | $18.58 | 2023 | Gvoke Hypopen |
| Supernus Pharmaceuticals, INC. | $15.15 | 2023 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $14.28 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.